MOONLAKE IMMUNO (MLTX)
(Delayed Data from NSDQ)
$46.65 USD
+1.68 (3.74%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $46.67 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Brokerage Reports
MoonLake Immunotherapeutics [MLTX]
Reports for Purchase
Showing records 1 - 20 ( 94 total )
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Regulatory Alignment on Phase 3 Psoriatic Arthritis Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Pivotal Sonelokimab Hidradenitis Suppurativa Program Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Clinical Programs Advance and Expand; 1Q24 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Bimzelx European Approval Further Validates IL-17A/F Class; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Komodo Health Partnership Unveiled; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor HS PsA Data Underscore SLK''s Best-in-Class Profile; Ph3s in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
SLK Impresses in ARGO @ 24wk; RD Day Outlines Catalysts & Indication Expansion
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
RD Day Showcases Sonelokimab Pole Position; Raising PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
SLK Pivotal Program; RD Day Next Week; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Q4/FY23: Gearing Up for SLK''s Advancement into Ph3 Trials; RD Day on March 10
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Phase 3 Design Mitigates Risk; Data Mid-2025; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
EOPh2 Puts SLK/HS on the Straight Path to Ph3 in Q2:24, PE Readout in Mid-2025
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
MoonLake Immunotherapeutics Management Call Invite - Dec. 7, 2023 at 10AM ET
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A